Europe Hemostats Market

September 2017 | 150 pages | ID: E01B2D6024DEN
Data Bridge Market Research

Abstracts

In this region, Europe hemostats market is projected to reach USD 1,093.7 million by 2024, from USD 641.6 million in 2016 growing at a CAGR of 6.9% in the forecast period 2017 to 2024.

Based on geography, the Europe hemostats market is segmented into 11 geographical regions, such as,

• Germany,
• France,
• United Kingdom,
• Italy,
• Spain,
• Russia,
• Turkey,
• Belgium,
• Netherlands,
• Switzerland and
• Rest of Europe.

Europe hemostats market competition by top players including

Ethicon US LLC (U.S.) is dominating the hemostats market followed by Pfizer and C.R. Bard Inc., along with others such as

• Baxter,
• Vascular Solutions, Inc.,
• B.Braun Melsungen,
• 3-D Matrix, Ltd.,
• Resorba Medical GmbH (an Advanced Medical Solutions Group plc Company),
• Anika Therapeutics, Inc.,
• Arch Therapeutics Inc.,
• Biom’Up SAS,
• CryoLife, Inc.,
• Gamma Therapeutics, Inc.,
• Hemostasis, LLC,
• MedTrade Products Limited, I
• ntegra LifeSciences Corporation,
• Medline Industries, Inc.,
• HEMOTEC MEDICAL GMBH,
• Stryker,
• CSL Behring,
• Mallinckrodt,
• Equimedical, B.V.

The Europe hemostats market is segmented on the basis of type, application, distribution channel, and end user.

The Europe hemostats market is segmented into 5 major types, namely thrombin based hemostats, combination agents, oxidized regenerated cellulose based haemostats, gelatin based haemostats and collagen based haemostats.

On the basis of application, the market is segmented into surgery and wound closure.

On the basis of end users, the market is classified into hospitals, community healthcare, ambulatory centres and clinics.

Contents

1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF EUROPE HEMOSTATS MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCE
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS
  3.1.1. CHRONIC CONDITIONS AND AGING POPULATION LEADING TO INCREASE IN NUMBER OF SURGICAL PROCEDURES
  3.1.2. TECHNOLOGICAL ADVANCEMENTS
  3.1.3. INCREASING NUMBER OF MINIMALLY INVASIVE SURGERIES
  3.1.4. IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING HEALTHCARE SPENDING
3.2. RESTRAINTS
  3.2.1. RELUCTANCE OF SURGEONS TOWARDS NEW PRODUCTS
  3.2.2. WEAK REIMBURSEMENT
3.3. OPPORTUNITIES
  3.3.1. UNMET MEDICAL NEEDS
  3.3.2. EMERGING MARKET
3.4. CHALLENGES
  3.4.1. DEVELOPMENT OF SUBSTITUTE PRODUCTS
  3.4.2. LIMITATIONS OF HEMOSTATIC AGENTS IN ACHIEVING HEMOSTASIS

4. PREMIUM INSIGHTS

5. REGULATORY

5.1. OVERVIEW
5.2. REGULATORY PROCEDURE

6. REIMBURSEMENT

6.1. OVERVIEW
6.2. REIMBURSEMENT SCENARIO

7. EXECUTIVE SUMMARY

8. EUROPE HEMOSTATS MARKET, BY TYPE

8.1. OVERVIEW
8.2. THROMBIN BASED HEMOSTATS
8.3. COMBINATION AGENT HEMOSTATS
8.4. OXIDIZED REGENERATED CELLULOSE BASED HEMOSTATS
8.5. GELATIN BASED HEMOSTATS
8.6. COLLAGEN BASED HEMOSTATS

9. EUROPE HEMOSTATS MARKET,BY APPLICATION

9.1. OVERVIEW
9.2. EUROPE HEMOSTATS MARKET, BY APPLICATION
9.3. WOUND CLOSURE
9.4. SURGICAL HEMOSTATS

10. EUROPE HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL

10.1. OVERVIEW
  10.1.1. DIRECT TENDERS
  10.1.2. RETAIL

11. EUROPE HEMOSTATS MARKET, BY END USER

11.1. OVERVIEW
11.2. HOSPITALS
11.3. AMBULATORY CENTERS
11.4. COMMUNITY HEALTHCARE
11.5. CLINICS

12. EUROPE HEMOSTATS MARKET, BY GEOGRAPHY

12.1. OVERVIEW
12.2. EUROPE
  12.2.1. GERMANY
  12.2.2. FRANCE
  12.2.3. U.K.
  12.2.4. ITALY
  12.2.5. SPAIN
  12.2.6. RUSSIA
  12.2.7. TURKEY
  12.2.8. BELGIUM
  12.2.9. NETHERLANDS
  12.2.10. SWITZERLAND
  12.2.11. REST OF EUROPE

13. EUROPE HEMOSTATS MARKET, COMPANY LANDSCAPE

13.1. COMPANY SHARE ANALYSIS: EUROPE
13.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
13.3. COMPANY SHARE ANALYSIS: EUROPE
13.4. COMPANY SHARE ANALYSIS: APAC

14. COMPANY PROFILES

14.1. ETHICON US, LLC (SUBSIDIARY OF JOHNSON &
JOHNSON SERVICES, INC)
  14.1.1. COMPANY OVERVIEW
  14.1.2. REVENUE ANALYSIS
  14.1.3. PRODUCT PORTFOLIO
  14.1.4. RECENT DEVELOPMENTS
14.2. PFIZER
  14.2.1. COMPANY OVERVIEW
  14.2.2. REVENUE ANALYSIS
  14.2.3. PRODUCT PORTFOLIO
  14.2.4. RECENT DEVELOPMENTS
14.3. C.R BARD
  14.3.1. COMPANY OVERVIEW
  14.3.2. REVENUE ANALYSIS
  14.3.3. PRODUCT PORTFOLIO
  14.3.4. RECENT DEVELOPMENTS
14.4. BAXTER
  14.4.1. COMPANY OVERVIEW
  14.4.2. REVENUE ANALYSIS
  14.4.3. PRODUCT PORTFOLIO
  14.4.4. RECENT DEVELOPMENTS
14.5. VASCULAR SOLUTIONS, INC
(ACQUIRED BY TELEFLEX INCORPORATED)
  14.5.1. COMPANY OVERVIEW
  14.5.2. REVENUE ANALYSIS
  14.5.3. PRODUCT PORTFOLIO
  14.5.4. RECENT DEVELOPMENTS
14.6. B.BRAUN MELSUNGEN AG
  14.6.1. COMPANY OVERVIEW
  14.6.2. REVENUE ANALYSIS
  14.6.3. PRODUCT PORTFOLIO
  14.6.4. RECENT DEVELOPMENTS
14.7. 3-D MATRIX LTD
  14.7.1. COMPANY OVERVIEW
  14.7.2. REVENUE ANALYSIS
  14.7.3. PRODUCT PORTFOLIO
  14.7.4. RECENT DEVELOPMENTS
14.8. RESORBA MEDICAL GMBH
  14.8.1. COMPANY OVERVIEW
  14.8.2. REVENUE ANALYSIS
  14.8.3. PRODUCT PORTFOLIO
  14.8.4. RECENT DEVELOPMENTS
14.9. ANIKA THERAPEUTICS, INC.
  14.9.1. COMPANY OVERVIEW
  14.9.2. REVENUE ANALYSIS
  14.9.3. PRODUCT PORTFOLIO
  14.9.4. RECENT DEVELOPMENTS
14.10. BIOM’UP
  14.10.1. COMPANY OVERVIEW
  14.10.2. REVENUE ANALYSIS
  14.10.3. PRODUCT PORTFOLIO
  14.10.4. RECENT DEVELOPMENTS
14.11. CRYOLIFE, INC.
  14.11.1. COMPANY OVERVIEW
  14.11.2. REVENUE ANALYSIS
  14.11.3. PRODUCT PORTFOLIO
  14.11.4. RECENT DEVELOPMENTS
14.12. EQUIMEDICAL
  14.12.1. COMPANY OVERVIEW
  14.12.2. REVENUE ANALYSIS
  14.12.3. PRODUCT PORTFOLIO
  14.12.4. RECENT DEVELOPMENTS
14.13. HEMOSTASIS, LLC
  14.13.1. COMPANY OVERVIEW
  14.13.2. REVENUE ANALYSIS
  14.13.3. PRODUCT PORTFOLIO
  14.13.4. RECENT DEVELOPMENTS
14.14. MEDTRADE PRODUCTS LIMITED
  14.14.1. COMPANY OVERVIEW
  14.14.2. REVENUE ANALYSIS
  14.14.3. PRODUCT PORTFOLIO
  14.14.4. RECENT DEVELOPMENTS
14.15. STRYKER
  14.15.1. COMPANY OVERVIEW
  14.15.2. REVENUE ANALYSIS
  14.15.3. PRODUCT PORTFOLIO
  14.15.4. RECENT DEVELOPMENTS
14.16. ARCH THERAPEUTICS, INC.
  14.16.1. COMPANY OVERVIEW
  14.16.2. REVENUE ANALYSIS
  14.16.3. PRODUCT PORTFOLIO
  14.16.4. RECENT DEVELOPMENTS
14.17. INTEGRA LIFESCIENCES CORPORATION
  14.17.1. COMPANY OVERVIEW
  14.17.2. REVENUE ANALYSIS
  14.17.3. PRODUCT PORTFOLIO
  14.17.4. RECENT DEVELOPMENTS
14.18. ALTAYLAR MEDICAL
  14.18.1. COMPANY OVERVIEW
  14.18.2. REVENUE ANALYSIS
  14.18.3. PRODUCT PORTFOLIO
  14.18.4. RECENT DEVELOPMENTS
14.19. BIOCER ENTWICKLUNGS-GMBH
  14.19.1. COMPANY OVERVIEW
  14.19.2. REVENUE ANALYSIS
  14.19.3. PRODUCT PORTFOLIO
  14.19.4. RECENT DEVELOPMENTS
14.20. SMI (STARCH MEDICAL)
  14.20.1. COMPANY OVERVIEW
  14.20.2. REVENUE ANALYSIS
  14.20.3. PRODUCT PORTFOLIO
  14.20.4. RECENT DEVELOPMENTS

15. RELATED REPORTS

TABLE LIST

TABLE 1 EUROPE HEMOSTATS S MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION)
TABLE 2 EUROPEHEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
TABLE 3 EUROPE HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 4 EUROPE HEMOSTATS MARKET, BY END USER,2015 – 2024 (USD MILLION)
TABLE 5 EUROPE HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 6 GERMANYHEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
TABLE 7 GERMANY HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 8 GERMANY HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 9 GERMANY HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 10 FRANCE HEMOSTATS MARKET, BY PRODUCT TYPE,2015 – 2024(USD MILLION)
TABLE 11 FRANCE HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 12 FRANCE HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 13 FRANCE HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 14 U.K. HEMOSTATS MARKET, BY PRODUCT TYPE,2015 – 2024(USD MILLION)
TABLE 15 U.K. HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 16 U.K. HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 17 U.K. HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 18 ITALY HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 19 ITALY HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 20 ITALY HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 21 ITALY HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 22 SPAIN HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 23 SPAIN HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 24 SPAIN HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 25 SPAIN HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 26 RUSSIA HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 27 RUSSIA HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 28 RUSSIA HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 29 RUSSIA HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 30 TURKEY HEMOSTATS MARKET, BY PRODUCT TYPE,2015 – 2024(USD MILLION)
TABLE 31 TURKEY HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 32 TURKEY HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 33 TURKEY HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 34 BELGIUM HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 35 BELGIUM HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 36 BELGIUM HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 37 BELGIUM HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 38 NETHERLANDS HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 39 NETHERLANDS HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 40 NETHERLANDS HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 41 NETHERLANDS HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 42 SWITZERLAND HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
TABLE 43 SWITZERLAND HEMOSTATS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
TABLE 44 SWITZERLAND HEMOSTATS MARKET, BY END USER, 2015 – 2024 (USD MILLION)
TABLE 45 SWITZERLAND HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
TABLE 46 REST OF EUROPE HEMOSTATS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

Figures

FIGURES LIST

FIGURE 1 EUROPE HEMOSTATS MARKET SNAPSHOT (2017)
FIGURE 2 EUROPE HEMOSTATS MARKET: BY GEOGRAPHY (2016)
FIGURE 3 EUROPE HEMOSTATS MARKET:BY COUNTRY (2017)
FIGURE 4 EUROPE HEMOSTATS MARKET BY COUNTRY (2016 & 2024)
FIGURE 5 EUROPE HEMOSTATS MARKET BY PRODUCT TYPE (2017 & 2024)
FIGURE 6 EUROPE HEMOSTATS MARKET: COMPANY SHARE 2016 (%)

COMPNIES PROFILES

Baxter, Vascular Solutions, Inc., B.Braun Melsungen, 3-D Matrix, Ltd., Resorba Medical GmbH (an Advanced Medical Solutions Group plc Company), Anika Therapeutics, Inc., Arch Therapeutics Inc., Biom’Up SAS, CryoLife, Inc., Gamma Therapeutics, Inc., Hemostasis, LLC